Hepatitis B vaccine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Bot: Removing from Primary care)
 
(48 intermediate revisions by 5 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Hepatitis B}}
{{Hepatitis B}}
{{CMG}}{{AE}}{{SaraM}}
{{CMG}}; {{AE}} {{SaraM}}


==Overview==
==Overview==
[[Hepatitis B vaccine]] is the most effective tool in preventing the [[transmission]] of [[HBV]] and [[HDV]]. [[Vaccines]] are composed of the surface antigen of HBV ([[HBsAg]]) and are produced by two different methods: plasma-derived and recombinant DNA.
The primary hepatitis B immunization series conventionally consists of three doses of vaccine. Vaccination of infants and, in particular, delivery of hepatitis B vaccine within 24 hours of birth is 90–95% effective in preventing HBV infection, as well as decreasing HBV transmission if followed by at least two other doses. [[WHO]] recommends universal hepatitis B vaccination for all [[infants]] and recommends that the first dose be given as soon as possible after birth.<ref name="WHO-Guideline-Hepatitis-B">World Health Organization, Guidelines for the Prevention, Care, and Treatment of persons with chronic Hepatitis B Infection. (March 2015). http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf Accessed on October 4th, 2016</ref><ref name="Hepatitis-B-Vac">Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV- infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS. 2013;24(2):117–22.</ref> This strategy has resulted in a dramatic decrease in the prevalence of CHB among young children in regions of the world where universal infant vaccination programs have been implemented. A proportion of vaccinated children (5–10%) have a poor response to vaccination, and will remain susceptible as adults to acquisition of HBV infection.<ref name="WHO-Guideline-Hepatitis-B">World Health Organization, Guidelines for the Prevention, Care, and Treatment of persons with chronic Hepatitis B Infection. (March 2015). http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf Accessed on October 4th, 2016</ref><ref name="hepatitis-B-virus">Liu CJ, Liou JM, Chen DS, Chen P J.Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc Taiwan. 2005;104(11):783–91.</ref> [[WHO]] recommends that [[hepatitis B vaccine]] be included in routine [[immunization]] services in all countries. The primary objective of hepatitis B [[immunization]] is to prevent chronic HBV infections, which result in [[chronic liver disease]] later in life. By preventing chronic HBV infections, the major reservoir for transmission of new infections is also reduced.<ref name="WHO-Guideline-Hepatitis-B">World Health Organization, Guidelines for the Prevention, Care, and Treatment of persons with chronic Hepatitis B Infection. (March 2015). http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf Accessed on October 4th, 2016</ref>


==Hepatitis B Vaccine==
==Hepatitis B Vaccine==
'''Hepatitis B vaccine''' is a [[vaccine]] developed for the prevention of hepatitis B virus infection. These rely on the use of one of the viral envelope proteins (hepatitis B surface antigen or HBsAg). The vaccine was originally prepared from plasma obtained from patients who had long-standing hepatitis B virus infection. However, currently, these are more often made using recombinant DNA technology, though plasma-derived vaccines continue to be used; the two types of vaccines are equally effective and safe.{{Fact|date=June 2007}}
'''Hepatitis B vaccine''' is a [[vaccine]] developed for the prevention of hepatitis B virus infection.
Hepatitis B vaccination is the most effective measure to prevent HBV infection and its consequences. Since they were first issued in 1982, recommendations for hepatitis B vaccination have evolved into a comprehensive strategy to eliminate HBV transmission in the United States.<ref name="pmid17159833">{{cite journal| author=Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L et al.| title=A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. | journal=MMWR Recomm Rep | year= 2006 | volume= 55 | issue= RR-16 | pages= 1-33; quiz CE1-4 | pmid=17159833 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17159833  }} </ref><ref name="USPTF-Hepatitis-B">US. Preventive Services Task Force. Screening for Hepatitis B infection. (2014) https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-b-virus-infection-screening-2014?ds=1&s=hepatitis%20b Accessed on October 4th, 2016</ref>


Many countries now routinely vaccinate infants against hepatitis B. Babies born to HBeAg positive mothers are strongly recommended to be vaccinated and injected with immune globulin immediately after birth, so as to prevent transmission of infection. In many areas, vaccination against hepatitis B is also required for all health-care workers. Some college campus housing units now require proof of vaccination as a prerequisite. Booster doses are not needed for low-risk general population. Some recommend such doses every five to ten years for health-care workers, though the evidence supporting such doses is quite limited.
Recombinant DNA-derived vaccines against HBV have been available for more than two decades. The primary hepatitis B immunization series conventionally consists of three doses of vaccine. Vaccination of infants and, in particular, administration of hepatitis B vaccine within 24 hours of birth is 90–95% effective in preventing infection with HBV as well as decreasing HBV transmission if followed by at least two other doses. [[WHO]] recommends universal hepatitis B vaccination for all [[infants]] and suggests that the first dose be given as soon as possible after birth.<ref name="WHO-Guideline-Hepatitis-B">World Health Organization, Guidelines for the Prevention, Care, and Treatment of persons with chronic Hepatitis B Infection. (March 2015). http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf Accessed on October 4th, 2016</ref><ref name="Hepatitis-B-Vac">Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV- infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS. 2013;24(2):117–22.</ref> This strategy has resulted in a dramatic decrease in the prevalence of CHB among young children in regions of the world where universal infant vaccination programs have been implemented. A small proportion of vaccinated children (5–10%) have a poor response to vaccination and remain susceptible to acquisition of HBV infection throughout their lives.<ref name="WHO-Guideline-Hepatitis-B">World Health Organization, Guidelines for the Prevention, Care, and Treatment of persons with chronic Hepatitis B Infection. (March 2015). http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf Accessed on October 4th, 2016</ref><ref name="hepatitis-B-virus">Liu CJ, Liou JM, Chen DS, Chen P J.Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc Taiwan. 2005;104(11):783–91.</ref>


The vaccine is highly effective. In endemic countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer. This was reported in [[Taiwan]] where the implementation of a nationwide hepatitis B vaccination program in 1984 was associated with a decline in the incidence of childhood [[hepatocellular carcinoma]].<ref name=Chang_1997>{{cite journal | author=Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Chau WY, Chen DS | title=Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group | journal=N Engl J Med | year=1997 | pages=1855-9 | volume=336 | issue=26  | id= PMID 9197213 }}</ref> In that sense, this vaccine can be thought of as an anti-cancer vaccine.
The vaccine is highly effective. In [[endemic|endemic countries]] with high rates of hepatitis B infection, the vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in [[liver cancer]]. This was reported in Taiwan, where the implementation of a nationwide hepatitis B vaccination program in 1984 was associated with a decline in the incidence of childhood [[hepatocellular carcinoma]].<ref name="Chang_1997">{{cite journal | author=Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Chau WY, Chen DS | title=Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group | journal=N Engl J Med | year=1997 | pages=1855-9 | volume=336 | issue=26  | id= PMID 9197213 }}</ref>


Patients with HIV appear to have inferior antibody responses to hepatitis B vaccination.<ref name=Pasricha_2006>{{cite journal |author=Pasricha N, Datta U, Chawla Y, Singh S, Arora S, Sud A, Minz R, Saikia B, Singh H, James I, Sehgal S |title=Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine |journal=BMC Infect Dis |volume=6 |issue= |pages=65 |year=2006 |pmid=16571140}}</ref> This is not surprising, because some HIV-positive people have damaged immune systems: this may happen even before opportunistic infections take hold, thus justifying a diagnosis of [[AIDS]].
Patients with [[HIV]] appear to have inferior antibody responses to hepatitis B vaccination. This is not surprising, as some HIV-positive patients have damaged immune systems; this may happen even before [[opportunistic infections]] take hold, thus justifying a diagnosis of [[AIDS]].<ref name="Pasricha_2006">{{cite journal |author=Pasricha N, Datta U, Chawla Y, Singh S, Arora S, Sud A, Minz R, Saikia B, Singh H, James I, Sehgal S |title=Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine |journal=BMC Infect Dis |volume=6 |issue= |pages=65 |year=2006 |pmid=16571140}}</ref>


It is not known whether vaccination with hepatitus B vaccine would cause rejection of a donor's blood by a blood bank that routinely tests blood for hepatitus B antibodies, as most now do—and have been doing since the mid-1980's. This is worth discussing with a doctor.
===Types of Vaccines===
The vaccine was originally prepared from plasma obtained from patients with long-standing hepatitis B virus infections. However, currently, they are more commonly made using recombinant DNA technology, though plasma-derived vaccines continue to be used in some places. The two types of vaccines are equally effective and safe.<ref name="pmid6997738">{{cite journal| author=Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC et al.| title=Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. | journal=N Engl J Med | year= 1980 | volume= 303 | issue= 15 | pages= 833-41 | pmid=6997738 | doi=10.1056/NEJM198010093031501 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6997738  }} </ref>
* Plasma derived
* Recombinant DNA
**Yeast-derived recombinant
**Mammalian cell-derived recombinant


Another question has arisen: What is the value of vaccinating an infant against a sexually-transmitted disease, using a vaccine that confers immunity for only seven years? This point has been raised by [[Judith Reisman]], whose credibility on other matters is suspect, but this point seems cogent. Unless the parents expected the child to be molested at an unusually early age, the vaccination would probably be wasted. Of course, the child might have consensual sex at 15 or 17, and the immunity might last longer than the guarantee, in which case it might help. (Is there a guarantee? In most jurisdictions, the [[statute of limitations]] for civil suits is one to three years, so a seven-year guarantee would be inherently unenforceable.) Alternatively, the parents might arrange for booster vaccinations every seven years: at 21 years, the booster might be needed, because most 21-year-olds have sex at least occasionally. {{Fact|date=September 2007}}
===Licensed hepatitis B vaccines in the United States===
Currently licensed hepatitis B vaccines in the United States include:<ref name="CDC-Hepatitis-B">Centers for Disease Control and Prevention. Hepatitis B (2016) http://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ Accessed on September 29, 2016</ref>
*Single-antigen hepatitis B vaccines
**ENGERIX-B
**RECOMBIVAX HB
*Combination vaccines
**PEDIARIX: Combined hepatitis B, diphtheria, tetanus, acellular pertussis (DTaP), and inactivated poliovirus (IPV) vaccine. Cannot be administered before age 6 weeks or after age 7 years.
**TWINRIX: Combined hepatitis A and hepatitis B vaccine. Recommended for persons aged ≥18 years who are at increased risk for both Hepatitis A virus and HBV infections.
**COMVAX (discontinued for purchase as of December 2014): Combined hepatitis B-Haemophilus influenzae type b (Hib) conjugate vaccine. Cannot be administered before age 6 weeks or after age 15 months.


The hepatitis B vaccine is the mainstay of hepatitis B prevention. WHO recommends that all infants receive the hepatitis B vaccine as soon as possible after birth, preferably within 24 hours. The birth dose should be followed by 2 or 3 doses to complete the primary series. In most cases, 1 of the following 2 options is considered appropriate:
a 3-dose schedule of hepatitis B vaccine, with the first dose (monovalent) being given at birth and the second and third (monovalent or combined vaccine) given at the same time as the first and third doses of diphtheria, pertussis (whooping cough), and tetanus – (DTP) vaccine; or
a 4-dose schedule, where a monovalent birth dose is followed by three monovalent or combined vaccine doses, usually given with other routine infant vaccines.
The complete vaccine series induces protective antibody levels in more than 95% of infants, children and young adults. Protection lasts at least 20 years and is probably lifelong. Thus, WHO does not recommend booster vaccination for persons who have completed the 3 dose vaccination schedule.
All children and adolescents younger than 18 years-old and not previously vaccinated should receive the vaccine if they live in countries where there is low or intermediate endemicity. In those settings it is possible that more people in high-risk groups may acquire the infection and they should also be vaccinated. They include:
people who frequently require blood or blood products, dialysis patients, recipients of solid organ transplantations;
people interned in prisons;
persons who inject drugs;
household and sexual contacts of people with chronic HBV infection;
people with multiple sexual partners;
health-care workers and others who may be exposed to blood and blood products through their work; and
travellers who have not completed their hepatitis B vaccination series, who should be offered the vaccine before leaving for endemic areas.
The vaccine has an excellent record of safety and effectiveness. Since 1982, over 1 billion doses of hepatitis B vaccine have been used worldwide. In many countries where between 8–15% of children used to become chronically infected with the hepatitis B virus, vaccination has reduced the rate of chronic infection to less than 1% among immunized children.
As of 2014, 184 Member States vaccinate infants against hepatitis B as part of their vaccination schedules and 82% of children in these states received the hepatitis B vaccine. This is a major increase compared with 31 countries in 1992, the year that the World Health Assembly passed a resolution to recommend global vaccination against hepatitis B. Furthermore, as of 2014, 96 Member States have introduced the hepatitis B birth dose vaccine.
In addition, implementing of blood safety strategies, including quality-assured screening of all donated blood and blood components used for transfusion, can prevent transmission of HBV. Safe injection practices, eliminating unnecessary and unsafe injections, can be effective strategies to protect against HBV transmission. Furthermore, safer sex practices, including minimizing the number of partners and using barrier protective measures (condoms), also protect against transmission.
Recombinant DNA-derived vaccines against HBV have been available for more than two decades. The primary hepatitis B immunization series conventionally consists of three doses of vaccine. Vaccination of infants and, in particular, delivery of hepatitis B vaccine within 24 hours of birth is 90–95% effective in preventing infection with HBV as well as decreasing HBV transmission if followed by at least two other doses. WHO recommends universal hepatitis B vaccination for all infants, and that the first dose should be given as soon as possible after birth.<ref Name=Hepatitis-B-Vac>Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV- infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS. 2013;24(2):117–22.</ref>This strategy has resulted in a dramatic decrease in the prevalence of CHB among young children in regions of the world where universal infant vaccination programs have been implemented. A proportion of vaccinated children (5–10%) have a poor response to vaccination, and will remain susceptible as adults to acquisition of HBV infection.:<ref name=WHO-Guideline-Hepatitis-B> World Health Organization, Guidelines for the Prevention, Care, and Treatment of persons with chronic Hepatitis B Infection. (March 2015). http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf Accessed on October 4th, 2016</ref><ref name=hepatitis-B-virus>Liu CJ, Liou JM, Chen DS, Chen P J.Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc Taiwan. 2005;104(11):783–91.</ref>
===Vaccination recommendation===
===Vaccination recommendation===
Hepatitis B vaccination recommendation in Infant and neonates include:<ref name=WHO-Guideline-Hepatitis-B> World Health Organization, Guidelines for the Prevention, Care, and Treatment of persons with chronic Hepatitis B Infection. (March 2015). http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf Accessed on October 4th, 2016</ref>
Hepatitis B vaccination recommendation in '''Infant and neonates''' includes:<ref name="WHO-Guideline-Hepatitis-B">World Health Organization, Guidelines for the Prevention, Care, and Treatment of persons with chronic Hepatitis B Infection. (March 2015). http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf Accessed on October 4th, 2016</ref>
*All infants should receive their first dose of hepatitis B vaccine as soon as possible after birth, preferably within 24 hours, followed by two or three doses.
*All infants should receive their first dose of hepatitis B vaccine as soon as possible after birth, preferably within 24 hours, followed by two or three additional doses.
Hepatitis B vaccination recommendation in adults include:<ref name=CDC-Hepatitis-B>Centers for Disease Control and Prevention. Hepatitis B (2016) http://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ Accessed on September 29, 2016</ref><ref name=CDC-Hepatitis-Travel> Centers for Disease Control and Prevention. Infectious Diseases Related to Travel. Hepatitis B. (2015) http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/hepatitis-b#4621 Accessed on October 4th, 2016</ref>
Hepatitis B vaccination recommendation in '''adults''' include:<ref name="CDC-Hepatitis-B">Centers for Disease Control and Prevention. Hepatitis B (2016) http://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ Accessed on September 29, 2016</ref><ref name="CDC-Hepatitis-Travel">Centers for Disease Control and Prevention. Infectious Diseases Related to Travel. Hepatitis B. (2015) http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/hepatitis-b#4621 Accessed on October 4th, 2016</ref>
*Any person who wants to be protected from HBV infection
*Any person who wants to be protected from HBV infection
*Patient with diabetes mellitus (age 60 years or older with diabetes mellitus, at the discretion of the treating clinician)
*Patient with diabetes mellitus (age 60 years or older with diabetes mellitus, at the discretion of the treating clinician)
*Patient with end-stage renal disease, including patients receiving hemodialysis; HIV infection; or chronic liver disease
*Patient with end-stage renal disease, including patients receiving hemodialysis and patients with HIV or chronic liver disease
*Sexually active and not in a long-term, mutually monogamous relationship (e.g., more than 1 sex partner during the previous 6 months)
*Sexually active and not in a long-term, mutually monogamous relationship (e.g., more than 1 sex partner during the previous 6 months)
*Seeking evaluation or receiving treatment for a sexually transmitted infection (STI)
*Seeking evaluation or receiving treatment for a sexually transmitted infection (STI)
Line 55: Line 49:
**Public safety worker
**Public safety worker
**Trainee in a health professional or allied health school
**Trainee in a health professional or allied health school
*Residents or staff of an institution for persons with developmental disabilities
*Residents or staff of an institution for people with developmental disabilities
*Sex partner or household member of a person who is chronically infected with HBV (HBsAg-positive)
*Sexual partners or household members of a person who is chronically infected with HBV (HBsAg-positive)
*People living in correctional facilities
*People living in correctional facilities
*All teenagers ages 18 and younger who are not fully vaccinated
*All teenagers ages 18 and younger who are not fully vaccinated
*Planned travel to a country with high or intermediate prevalence of endemic HBV infection  
*People who plan to travel to a country with high or intermediate prevalence of [[endemic]] HBV infection  
**Hepatitis B vaccination should be administered to all unvaccinated people traveling to areas with intermediate to high prevalence of chronic hepatitis B (HBV surface antigen prevalence ≥2%)
**Hepatitis B vaccination should be administered to all unvaccinated people traveling to areas with intermediate to high prevalence of chronic hepatitis B (HBV surface antigen prevalence ≥2%)
[[Image:Screen Shot 2016-10-04 at 12.39.01 PM.png|800px|thumb|center]]
[[Image:Screen Shot 2016-10-04 at 12.39.01 PM.png|800px|thumb|center]]
===Contraindications===
Hepatitis B vaccine is contraindicated in a person who has experienced a serious systemic or anaphylactic reaction to a prior dose of the vaccine.


===Recommended schedule===
===Recommended schedule===
The vaccination schedule  
The vaccination schedule for children and adults involves 3 [[intramuscular injections]], the second and third doses administered 1 and 6 months after the first.
*Children and adults 3 [[intramuscular injections]], the second and third doses administered 1 and 6 months
 
===Licensed hepatitis B vaccines in the United States===
Currently licensed hepatitis B vaccines in the United States:<ref name=CDC-Hepatitis-B>Centers for Disease Control and Prevention. Hepatitis B (2016) http://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ Accessed on September 29, 2016</ref>|
*Single-antigen hepatitis B vaccines
**ENGERIX-B
**RECOMBIVAX HB
*Combination vaccines
**PEDIARIX: Combined hepatitis B, diphtheria, tetanus, acellular pertussis (DTaP), and inactivated poliovirus (IPV) vaccine. Cannot be administered before age 6 weeks or after age 7 years.
**TWINRIX: Combined Hepatitis A and hepatitis B vaccine. Recommended for persons aged ≥18 years who are at increased risk for both Hepatitis A virus and HBV infections.
**COMVAX: (discontinued for purchase as of December 2014): Combined hepatitis B-Haemophilus influenzae type b (Hib) conjugate vaccine. Cannot be administered before age 6 weeks or after age 71 months.
===Recommended doses of hepatitis B vaccines===
===Recommended doses of hepatitis B vaccines===
[[Image:Screen Shot 2016-10-04 at 11.43.46 AM.png|Recommended doses of hepatitis B vaccines<ref name=CDC-Hepatitis-B>Centers for Disease Control and Prevention. Hepatitis B (2016) http://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ Accessed on September 29, 2016</ref>|800px|thumb|center]]
[[Image:Screen Shot 2016-10-04 at 11.43.46 AM.png|Recommended doses of hepatitis B vaccines<ref name="CDC-Hepatitis-B">Centers for Disease Control and Prevention. Hepatitis B (2016) http://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ Accessed on September 29, 2016</ref>|800px|thumb|center]]
[[Image:Screen Shot 2016-10-04 at 11.50.13 AM.png|800px|thumb|center]]
[[Image:Screen Shot 2016-10-04 at 11.50.13 AM.png|800px|thumb|center]]
===Interrupted Vaccination===
===Interrupted Vaccination===
interruption between doses of hepatitis B vaccination:<ref name=CDC-Hepatitis-B>Centers for Disease Control and Prevention. Hepatitis B (2016) http://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ Accessed on September 29, 2016</ref>
interruption between doses of hepatitis B vaccination:<ref name="CDC-Hepatitis-B">Centers for Disease Control and Prevention. Hepatitis B (2016) http://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ Accessed on September 29, 2016</ref>
*After the first dose, the second dose should be administered as soon as possible
*After the first dose, the second dose should be administered as soon as possible
*The second and third doses should be separated by an interval of at least 8 weeks
*The second and third doses should be separated by an interval of at least 8 weeks
*Only the third dose is delayed, it should be administered as soon as possible
*If only the third dose is delayed, it should be administered as soon as possible
 
===Contraindications===
Hepatitis B vaccine is contraindicated in a person who has experienced a serious systemic or anaphylactic reaction to a prior dose of the vaccine.


==References==
=== Booster Doses===
{{reflist|2}}
Booster doses are not recommended for persons with a normal immune status who were vaccinated as infants, children, or adolescents. Annual antibody to hepatitis B surface antigen testing will determine the need for booster. The booster should be considered when anti-HBs levels decline to <10 mIU/mL should be considered in persons with an ongoing high risk for exposure.<ref name="MMWR-Hepatitis-B">Morbidity and Mortality Weekly Report. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States. (2006). http://www.cdc.gov/mmwr/PDF/rr/rr5516.pdf Accessed on October 4th, 2016 </ref><ref name="MMWR-Hepatitis">Centers for Disease Control and Prevention. Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5201a1.htm  Accessed on October 4th 2016</ref>
<!-- ---------------------------------------------------------------
*Serologic testing is not recommended to assess antibody levels in any age group, except in specific circumstances, as outlined below:
See http://en.wikipedia.org/wiki/Wikipedia:Footnotes for a
**[[Hemodialysis]] patients
discussion of different citation methods and how to generate
**[[Immunocompromised]] patients ([[HIV]]-infected patients, [[hematopoietic stem cell transplant]] recipients, and patients receiving [[chemotherapy]])
footnotes using the <ref> & </ref> tags and the {{Reflist}} template
-------------------------------------------------------------------- -->
<!-- {{Reflist|2}} -->


==See also==
==References ==  
*[http://www.rapidtest.com elisakits]
{{Reflist|2}}
*[[Twinrix]]


{{Vaccines}}
{{WH}}
{{WS}}


[[Category:Vaccines]]
[[Category:Gastroenterology]]
{{WikiDoc Sources}}
[[Category:FinalQCRequired]]
[[Category:Emergency mdicine]]
[[Category:Disease]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Hepatology]]

Latest revision as of 22:05, 29 July 2020

Hepatitis Main Page

Hepatitis B

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hepatitis B from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatitis B vaccine On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis B vaccine

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis B vaccine

CDC on Hepatitis B vaccine

Hepatitis B vaccine in the news

Blogs on Hepatitis B vaccine

Directions to Hospitals Treating Hepatitis B

Risk calculators and risk factors for Hepatitis B vaccine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mehrsefat, M.D. [2]

Overview

Hepatitis B vaccine is the most effective tool in preventing the transmission of HBV and HDV. Vaccines are composed of the surface antigen of HBV (HBsAg) and are produced by two different methods: plasma-derived and recombinant DNA. The primary hepatitis B immunization series conventionally consists of three doses of vaccine. Vaccination of infants and, in particular, delivery of hepatitis B vaccine within 24 hours of birth is 90–95% effective in preventing HBV infection, as well as decreasing HBV transmission if followed by at least two other doses. WHO recommends universal hepatitis B vaccination for all infants and recommends that the first dose be given as soon as possible after birth.[1][2] This strategy has resulted in a dramatic decrease in the prevalence of CHB among young children in regions of the world where universal infant vaccination programs have been implemented. A proportion of vaccinated children (5–10%) have a poor response to vaccination, and will remain susceptible as adults to acquisition of HBV infection.[1][3] WHO recommends that hepatitis B vaccine be included in routine immunization services in all countries. The primary objective of hepatitis B immunization is to prevent chronic HBV infections, which result in chronic liver disease later in life. By preventing chronic HBV infections, the major reservoir for transmission of new infections is also reduced.[1]

Hepatitis B Vaccine

Hepatitis B vaccine is a vaccine developed for the prevention of hepatitis B virus infection. Hepatitis B vaccination is the most effective measure to prevent HBV infection and its consequences. Since they were first issued in 1982, recommendations for hepatitis B vaccination have evolved into a comprehensive strategy to eliminate HBV transmission in the United States.[4][5]

Recombinant DNA-derived vaccines against HBV have been available for more than two decades. The primary hepatitis B immunization series conventionally consists of three doses of vaccine. Vaccination of infants and, in particular, administration of hepatitis B vaccine within 24 hours of birth is 90–95% effective in preventing infection with HBV as well as decreasing HBV transmission if followed by at least two other doses. WHO recommends universal hepatitis B vaccination for all infants and suggests that the first dose be given as soon as possible after birth.[1][2] This strategy has resulted in a dramatic decrease in the prevalence of CHB among young children in regions of the world where universal infant vaccination programs have been implemented. A small proportion of vaccinated children (5–10%) have a poor response to vaccination and remain susceptible to acquisition of HBV infection throughout their lives.[1][3]

The vaccine is highly effective. In endemic countries with high rates of hepatitis B infection, the vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer. This was reported in Taiwan, where the implementation of a nationwide hepatitis B vaccination program in 1984 was associated with a decline in the incidence of childhood hepatocellular carcinoma.[6]

Patients with HIV appear to have inferior antibody responses to hepatitis B vaccination. This is not surprising, as some HIV-positive patients have damaged immune systems; this may happen even before opportunistic infections take hold, thus justifying a diagnosis of AIDS.[7]

Types of Vaccines

The vaccine was originally prepared from plasma obtained from patients with long-standing hepatitis B virus infections. However, currently, they are more commonly made using recombinant DNA technology, though plasma-derived vaccines continue to be used in some places. The two types of vaccines are equally effective and safe.[8]

  • Plasma derived
  • Recombinant DNA
    • Yeast-derived recombinant
    • Mammalian cell-derived recombinant

Licensed hepatitis B vaccines in the United States

Currently licensed hepatitis B vaccines in the United States include:[9]

  • Single-antigen hepatitis B vaccines
    • ENGERIX-B
    • RECOMBIVAX HB
  • Combination vaccines
    • PEDIARIX: Combined hepatitis B, diphtheria, tetanus, acellular pertussis (DTaP), and inactivated poliovirus (IPV) vaccine. Cannot be administered before age 6 weeks or after age 7 years.
    • TWINRIX: Combined hepatitis A and hepatitis B vaccine. Recommended for persons aged ≥18 years who are at increased risk for both Hepatitis A virus and HBV infections.
    • COMVAX (discontinued for purchase as of December 2014): Combined hepatitis B-Haemophilus influenzae type b (Hib) conjugate vaccine. Cannot be administered before age 6 weeks or after age 15 months.

Vaccination recommendation

Hepatitis B vaccination recommendation in Infant and neonates includes:[1]

  • All infants should receive their first dose of hepatitis B vaccine as soon as possible after birth, preferably within 24 hours, followed by two or three additional doses.

Hepatitis B vaccination recommendation in adults include:[9][10]

  • Any person who wants to be protected from HBV infection
  • Patient with diabetes mellitus (age 60 years or older with diabetes mellitus, at the discretion of the treating clinician)
  • Patient with end-stage renal disease, including patients receiving hemodialysis and patients with HIV or chronic liver disease
  • Sexually active and not in a long-term, mutually monogamous relationship (e.g., more than 1 sex partner during the previous 6 months)
  • Seeking evaluation or receiving treatment for a sexually transmitted infection (STI)
  • A male who has sex with males
  • A current or recent injection-drug user
  • At occupational risk of infection through exposure to blood or blood-contaminated body fluids
    • Health care worker
    • Public safety worker
    • Trainee in a health professional or allied health school
  • Residents or staff of an institution for people with developmental disabilities
  • Sexual partners or household members of a person who is chronically infected with HBV (HBsAg-positive)
  • People living in correctional facilities
  • All teenagers ages 18 and younger who are not fully vaccinated
  • People who plan to travel to a country with high or intermediate prevalence of endemic HBV infection
    • Hepatitis B vaccination should be administered to all unvaccinated people traveling to areas with intermediate to high prevalence of chronic hepatitis B (HBV surface antigen prevalence ≥2%)

Contraindications

Hepatitis B vaccine is contraindicated in a person who has experienced a serious systemic or anaphylactic reaction to a prior dose of the vaccine.

Recommended schedule

The vaccination schedule for children and adults involves 3 intramuscular injections, the second and third doses administered 1 and 6 months after the first.

Recommended doses of hepatitis B vaccines

Recommended doses of hepatitis B vaccines[9]

Interrupted Vaccination

interruption between doses of hepatitis B vaccination:[9]

  • After the first dose, the second dose should be administered as soon as possible
  • The second and third doses should be separated by an interval of at least 8 weeks
  • If only the third dose is delayed, it should be administered as soon as possible

Booster Doses

Booster doses are not recommended for persons with a normal immune status who were vaccinated as infants, children, or adolescents. Annual antibody to hepatitis B surface antigen testing will determine the need for booster. The booster should be considered when anti-HBs levels decline to <10 mIU/mL should be considered in persons with an ongoing high risk for exposure.[11][12]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 World Health Organization, Guidelines for the Prevention, Care, and Treatment of persons with chronic Hepatitis B Infection. (March 2015). http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf Accessed on October 4th, 2016
  2. ↑ 2.0 2.1 Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV- infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS. 2013;24(2):117–22.
  3. ↑ 3.0 3.1 Liu CJ, Liou JM, Chen DS, Chen P J.Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc Taiwan. 2005;104(11):783–91.
  4. ↑ Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L; et al. (2006). "A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults". MMWR Recomm Rep. 55 (RR-16): 1–33, quiz CE1-4. PMID 17159833.
  5. ↑ US. Preventive Services Task Force. Screening for Hepatitis B infection. (2014) https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-b-virus-infection-screening-2014?ds=1&s=hepatitis%20b Accessed on October 4th, 2016
  6. ↑ Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Chau WY, Chen DS (1997). "Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group". N Engl J Med. 336 (26): 1855–9. PMID 9197213.
  7. ↑ Pasricha N, Datta U, Chawla Y, Singh S, Arora S, Sud A, Minz R, Saikia B, Singh H, James I, Sehgal S (2006). "Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine". BMC Infect Dis. 6: 65. PMID 16571140.
  8. ↑ Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC; et al. (1980). "Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States". N Engl J Med. 303 (15): 833–41. doi:10.1056/NEJM198010093031501. PMID 6997738.
  9. ↑ 9.0 9.1 9.2 9.3 Centers for Disease Control and Prevention. Hepatitis B (2016) http://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ Accessed on September 29, 2016
  10. ↑ Centers for Disease Control and Prevention. Infectious Diseases Related to Travel. Hepatitis B. (2015) http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/hepatitis-b#4621 Accessed on October 4th, 2016
  11. ↑ Morbidity and Mortality Weekly Report. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States. (2006). http://www.cdc.gov/mmwr/PDF/rr/rr5516.pdf Accessed on October 4th, 2016
  12. ↑ Centers for Disease Control and Prevention. Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5201a1.htm Accessed on October 4th 2016

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Hepatitis_B_vaccine&oldid=1639146"